“…In their report, the secondary structure of BSA, especially -sheet content, was not disrupted by the encapsulation procedure (Castellanos et al, 2001a,b). Moreover, the effects of addition or covalent modification by PEG or cyclodextrins were investigated using ␣ or ␥-chymotrypsin as model proteins (Castellanos et al, , 2005a(Castellanos et al, , 2005b(Castellanos et al, , 2006Castellanos and Griebenow, 2003;Perez et al, 2002). A similar method has been used to prepare a PLGA microsphere containing vascular endothelial growth factor (Kim and Burgess, 2002), human growth hormone (hGH) (Takada et al, 2003), insulin (Kang and Singh, 2005;Andreas et al, 2011), immunoglobulin G (Wang et al, 2004), glial cell linederived neurotrophic factor (Checa-Casalengua et al, 2011), typical model proteins such as lysozyme, ␣-chymotrypsin, peroxidase and -galactosidase (Giteau et al, 2008), BSA-loaded calcium phosphate nanoparticles (Pitukmanorom et al, 2008), BSA-loaded dextran glassy particles (Yuan et al, 2010), recombinant human granulocyte colony-stimulating factor-loaded glassy sodium hyaluronate particles (Wu et al, 2011), recombinant human erythropoietin and human serum albumin mixture microparticles (He et al, 2011), BSA-or -galactosidasen-loaded dextran nanoparticles , BSA-loaded porous silicon microparticles (Fan et al, 2011) and zinc-BSA nanoparticles (Ma et al, 2012).…”